← All Cel Sci CORP filings

Cel Sci CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

AMEX
CVM
Cel Sci CORP
10-K: CEL-SCI Reports Strong Multikine Phase III Data, Faces Going Concern Doubt
CEL-SCI Corporation's latest 10-K filing highlights positive Phase III Multikine data for head and neck cancer, outlining plans for a confirmatory study while facing ongoing financial losses and a going concern doubt.
AMEX
CVM
Cel Sci CORP
10-K: CEL-SCI Corporation Reports Fiscal Year 2024 Results, Focuses on Multikine Confirmatory Study
CEL-SCI Corporation announces its fiscal year 2024 results, highlighting progress towards a confirmatory study for Multikine in head and neck cancer treatment.